Adicet Bio (GB:0HX7)
LSE:0HX7
0HX7 Stock Chart & Stats
$6.28
-$0.08(-7.54%)
At close: 4:00 PM EST
$6.28
-$0.08(-7.54%)
Day’s Range― - ―
52-Week Range$6.18 - $22.40
Previous CloseN/A
Volume2.90K
Average Volume (3M)138.00
Market Cap
$62.86M
Enterprise Value$38.70M
Total Cash (Recent Filing)$158.53M
Total Debt (Recent Filing)$14.74M
Price to Earnings (P/E)―
Beta1.96
Next Earnings
May 12, 2026EPS Estimate
-11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.94
Shares Outstanding9,596,407
10 Day Avg. Volume191
30 Day Avg. Volume138
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap0.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-26.27
Enterprise Value/Ebitda-0.33
Forecast
1Y Price Target
$38.00Price Target Upside505.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-32.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy In Autoimmune IndicationsPreliminary clinical data demonstrated strong renal responses and sustained reductions in lupus disease activity, supporting plans to pursue a pivotal trial in lupus nephritis and potential expansion into broader autoimmune indications.
Manufacturing Scalability And Pipeline DiversificationAn allogeneic, off-the-shelf therapy design combined with advancement of a PSMA-targeting armored CAR T candidate offers manufacturing scalability and pipeline diversification that could add commercial value if clinical activity is confirmed.
Safety And Outpatient Dosing AdvantageA benign safety profile that may permit outpatient dosing could improve patient convenience and provide a practical competitive advantage over existing therapies.
Bears Say
Analyst Report Conflict Of InterestDisclosed business relationships between the research provider and covered companies present a potential conflict of interest that could undermine perceived objectivity of analyst reports and investor confidence.
Execution And Regulatory RiskProgress depends on favorable clinical results and regulatory alignment, creating execution risk that could weigh on the share price if pivotal trials or agency discussions do not meet expectations.
Financial Risk And Valuation PressureHigher-than-expected operating expenses and the use of a larger discount factor reduced valuation, indicating increased financial risk and potential pressure on the stock if additional funding is required.
Adicet Bio News
0HX7 FAQ
What was Adicet Bio’s price range in the past 12 months?
Adicet Bio lowest share price was $6.18 and its highest was $22.40 in the past 12 months.
What is Adicet Bio’s market cap?
Adicet Bio’s market cap is $62.86M.
When is Adicet Bio’s upcoming earnings report date?
Adicet Bio’s upcoming earnings report date is May 12, 2026 which is in 33 days.
How were Adicet Bio’s earnings last quarter?
Adicet Bio released its earnings results on Mar 12, 2026. The company reported -$2.94 earnings per share for the quarter, missing the consensus estimate of -$2.91 by -$0.03.
Is Adicet Bio overvalued?
According to Wall Street analysts Adicet Bio’s price is currently Undervalued.
Does Adicet Bio pay dividends?
Adicet Bio pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Adicet Bio dividends here
What is Adicet Bio’s EPS estimate?
Adicet Bio’s EPS estimate is -11.
How many shares outstanding does Adicet Bio have?
Adicet Bio has 9,596,407 shares outstanding.
What happened to Adicet Bio’s price movement after its last earnings report?
Adicet Bio reported an EPS of -$2.94 in its last earnings report, missing expectations of -$2.91. Following the earnings report the stock price went up 5.849%.
Which hedge fund is a major shareholder of Adicet Bio?
Currently, no hedge funds are holding shares in GB:0HX7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adicet Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.00 (505.10% Upside)
$38.00 (505.10% Upside)
Blogger Sentiment
Bullish
GB:0HX7 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.77%
12-Months-Change
Fundamentals
Return on Equity
-82.96%
Trailing 12-Months
Asset Growth
-12.65%
Trailing 12-Months
Company Description
Adicet Bio
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
0HX7 Stock 12 Month Forecast
Average Price Target
$38.00
▲(505.10% Upside)
Technical Analysis
Sutro Biopharma
―
PMV Pharmaceuticals
―
Gain Therapeutics
―
Immix Biopharma
―
Artiva Biotherapeutics, Inc.
―